Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Recruiting 16Completed 3Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Advanced ER+, HER2-Negative Breast Cancer 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × elacestrant × Clear all
NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

NCT04797728 2022-10-26

ELIPSE

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed
23 enrolled
Breast

Breast Neoplasms

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡